{"database": "lobbying", "table": "lobbying_activities", "rows": [[2684661, "89c7f8ed-ccb8-495e-ace3-869d045caf65", "Q3", "BRAEBURN INC. FORMERLY KNOWN AS BRAEBURN PHARMACEUTICALS INC", 401104621, "BRAEBURN INC FORMERLY KNOWN AS BRAEBURN PHARMACEUTICALS INC", 2021, "third_quarter", "INS", "HR 1629, S250 Fairness in Orphan Drug Exclusivity Act; Administration of controlled substances by HCPs; Storage of controlled substances", "HOUSE OF REPRESENTATIVES,SENATE,White House Office", null, 100000, 0, 0, "2021-10-18T12:03:00.890000-04:00"]], "columns": ["id", "filing_uuid", "filing_type", "registrant_name", "registrant_id", "client_name", "filing_year", "filing_period", "issue_code", "specific_issues", "government_entities", "income_amount", "expense_amount", "is_no_activity", "is_termination", "received_date"], "primary_keys": ["id"], "primary_key_values": ["2684661"], "units": {}, "query_ms": 10.640161926858127, "source": "Federal Register API & Regulations.gov API", "source_url": "https://www.federalregister.gov/developers/api/v1", "license": "Public Domain (U.S. Government data)", "license_url": "https://www.regulations.gov/faq"}